Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Japan: A retrospective analysis of 1,057 cases from Kyushu Lymphoma Study Group

International Journal of Hematology

Volumn 91, Issue 2, 2010, Pages 258-266

  Seki, Ritsuko ^a,b   Ohshima, Koichi ^a,b   Nagafuji, Koji ^a   Fujisaki, Tomoaki ^c   Uike, Naokuni ^d   Kawano, Fumio ^e   Gondo, Hisashi ^f   Makino, Shigeyoshi ^g   Eto, Tetsuya ^h   Moriuchi, Yukiyoshi ⁱ   Taguchi, Fumihiro ^j   Kamimura, Tomohiko ^k   Tsuda, Hiroyuki ^l   Ogawa, Ryosuke ^m   Shimoda, Kazuya ⁿ   Yamashita, Kiyoshi ⁿ   Suzuki, Keiko ^o   Suzushima, Hitoshi ^p   Tsukazaki, Kunihiro ^q   Higuchi, Masakazu ^r   Utsunomiya, Atae ^s   Iwahashi, Masahiro ^t   Imamura, Yutaka ^u   Tamura, Kazuo ^v   Suzumiya, Junji ^w   Yoshida, Minoru ^x   Abe, Yasunobu ^y   Matsumoto, Tadashi ^z   Okamura, Takashi ^a,b   more..

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KURUME UNIVERSITY   (Japan)

^c MATSUYAMA RED CROSS HOSPITAL   (Japan)

^d NATIONAL KYUSHU CANCER CENTER   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION KUMAMOTO MEDICAL CENTER   (Japan)

^f Saga Prefectural Hospital Koseikan   (Japan)

^g MIYAZAKI PREFECTURAL MIYAZAKI HOSPITAL   (Japan)

^h HAMANOMACHI HOSPITAL   (Japan)

ⁱ Sasebo Shiritsu Sogo Hospital   (Japan)

^j ASO IIZUKA HOSPITAL   (Japan)

^k HARASANSHIN HOSPITAL   (Japan)

^l KUMAMOTO CITY HOSPITAL   (Japan)

^m Shimonoseki City Hospital   (Japan)

ⁿ UNIVERSITY OF MIYAZAKI   (Japan)

^o Koga General Hospital   (Japan)

^p NTT Kyushu General Hospital   (Japan)

^q NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^r KYUSHU KOSEI NENKIN HOSPITAL   (Japan)

^s IMAMURA BUN IN HOSPITAL   (Japan)

^t Saiseikai Hita Hospital   (Japan)

^u ST MARY S HOSPITAL   (Japan)

^v FUKUOKA UNIVERSITY HOSPITAL   (Japan)

^w Fukuoka University Chikushi Hospital   (Japan)

^x JAPANESE RED CROSS KUMAMOTO HOSPITAL   (Japan)

^y KYUSHU UNIVERSITY   (Japan)

^z Imamura Hospital   (Japan)

more..

Author keywords

CHOP; DLBCL; Prognosis; Radiation; Rituximab

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; METHOTREXATE; PIRARUBICIN; PREDNISOLONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; FEMALE; GROUPS BY AGE; HUMAN; HUMAN TISSUE; JAPAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; JAPAN; KAPLAN-MEIERS ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDNISONE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; VINCRISTINE;

EID: 77950916835     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-009-0475-2     Document Type: Article

References (34)

1. Fisher RI, Miller TP, O'Connor OA. Diffuse aggressive lymphoma. Hematol Am Soc Hematol Educ Progr. 2004;1:221-36.
2. The Research Group for Population-based Cancer Registration in Japan. Cancer incidence and incidence rates in Japan in 1995: estimates based on data from nine population-based cancer registries. The Research Group for Population-based Cancer Registration in Japan. Jpn J Clin Oncol. 2000;30:318-21.
3. T Izumo N Maseki S Mori E Tsuchiya 2000 Practical utility of the revised European-American classification of lymphoid neoplasms for Japanese non-Hodgkin's lymphomas Jpn J Cancer Res 91 351 360 1:CAS:528: DC%2BD3cXit1ejt7o%3D 10760696 (Pubitemid 30198177)
4. LI Gordon D Harrington J Andersen, et al. 1992 Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma N Engl J Med 327 342 349
5. RI Fisher ER Gaynor S Dahlberg, et al. 1993 Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma N Engl J Med 328 1002 1006 10.1056/NEJM199304083281404 1:STN:280:DyaK3s7ps1Kmtg%3D%3D 7680764 (Pubitemid 23095683)
6. M Ogura Y Morishima Y Kagami, et al. 2006 Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B-cell lymphoma Cancer Sci 97 305 312 10.1111/j.1349-7006.2006.00173.x 1:CAS:528:DC%2BD28XksVWksbg%3D 16630123
7. W Hiddemann M Kneba M Dreyling, et al. 2005 Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group Blood 106 3725 3732 10.1182/blood-2005-01-0016 1:CAS:528:DC%2BD2MXht12ksbjP 16123223 (Pubitemid 41742196)
8. D Shan JA Ledbetter OW Press 1998 Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies Blood 91 1644 1652 1:CAS:528:DyaK1cXht12gsbk%3D 9473230 (Pubitemid 28110329)
9. AR Jazirehi S Huerta-Yepez G Cheng B Bonavida 2005 Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis Cancer Res 65 264 276 1:CAS:528:DC%2BD2MXhvFamsQ%3D%3D 15665303 (Pubitemid 40070818)
10. AR Jazirehi B Bonavida 2005 Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention Oncogene 24 2121 2143 10.1038/sj.onc.1208349 1:CAS:528:DC%2BD2MXisFejuro%3D 15789036 (Pubitemid 40516580)
11. MI Vega AR Jazirehi S Huerta-Yepez B Bonavida 2005 Rituximab-induced inhibition of YY1 and Bcl-xL expression in Ramos non-Hodgkin's lymphoma cell line via inhibition of NF-kappa B activity: role of YY1 and Bcl-xL in Fas resistance and chemoresistance, respectively J Immunol 175 2174 2183 1:CAS:528:DC%2BD2MXntVSrtb4%3D 16081784 (Pubitemid 41113823)
12. B Coiffier E Lepage J Briere, et al. 2002 CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma N Engl J Med 346 235 242 10.1056/NEJMoa011795 1:CAS:528: DC%2BD38XmslGgsw%3D%3D 11807147 (Pubitemid 34438862)
13. M Pfreundschuh L Trumper A Osterborg, et al. 2006 CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group Lancet Oncol 7 379 391 10.1016/S1470-2045(06)70664-7 1:CAS:528:DC%2BD28XjvFWlsbw%3D 16648042
14. P Feugier A Van Hoof C Sebban, et al. 2005 Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte J Clin Oncol 23 4117 4126 10.1200/JCO.2005.09.131 1:CAS:528:DC%2BD2MXmt1elsr0%3D 15867204 (Pubitemid 46211317)
15. TM Habermann EA Weller VA Morrison, et al. 2006 Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma J Clin Oncol 24 3121 3127 10.1200/JCO.2005.05.1003 1:CAS:528:DC%2BD28XnslKhsL4%3D 16754935 (Pubitemid 46638950)
16. LH Sehn J Donaldson M Chhanabhai, et al. 2005 Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia J Clin Oncol 23 5027 5033 10.1200/JCO.2005.09.137 1:CAS:528:DC%2BD2MXpsFWmtLs%3D 15955905 (Pubitemid 46224009)
17. BD Cheson SJ Horning B Coiffier, et al. 1999 Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas NCI Sponsored International Working Group J Clin Oncol 17 1244 1:STN:280: DC%2BD3c%2FivF2itg%3D%3D 10561185
18. Jaffe ES, Harris NL, Stein H, Vardiman J. Pathology and genetics of tumors of the hematopoietic and lymphoid tissues. Lyon: IARC Press; 2001. p. 171-4.
19. B Saito E Shiozawa T Usui, et al. 2007 Rituximab with chemotherapy improves survival of non-germinal center type untreated diffuse large B-cell lymphoma Leukemia 21 2563 2566 10.1038/sj.leu.2404844 1:CAS:528: DC%2BD2sXhtlaksr7L 17597802 (Pubitemid 350148910)
20. H Nishimori K Matsuo Y Maeda, et al. 2009 The effect of adding rituximab to CHOP-based therapy on clinical outcomes for Japanese patients with diffuse large B-cell lymphoma: A propensity sore matching analysis Int J Hematol 89 326 331 10.1007/s12185-009-0259-8 1:CAS:528:DC%2BD1MXkt1yhurg%3D 19326060
21. O Hermine C Haioun E Lepage, et al. 1996 Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA) Blood 87 265 272 1:CAS:528:DyaK28Xit1SitQ%3D%3D 8547651
22. A Ichikawa T Kinoshita T Watanabe, et al. 1997 Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma N Engl J Med 337 529 534 10.1056/NEJM199708213370804 1:CAS:528:DyaK2sXlvV2gsb8%3D 9262496 (Pubitemid 27352019)
23. M Yamaguchi M Seto M Okamoto, et al. 2002 De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients Blood 99 815 821 10.1182/blood.V99.3.815 1:CAS:528:DC%2BD38XhtValsL0%3D 11806981 (Pubitemid 34525540)
24. R Seki T Okamura H Koga, et al. 2003 Prognostic significance of the F-box protein Skp2 expression in diffuse large B-cell lymphoma Am J Hematol 73 230 235 10.1002/ajh.10379 12879424 (Pubitemid 36898878)
25. kip1 in patients with diffuse large B-cell lymphoma: effects of rituximab. Ann Oncol. 2009 (in press).
26. IS Lossos D Morgensztern 2006 Prognostic biomarkers in diffuse large B-cell lymphoma J Clin Oncol 24 995 1007 10.1200/JCO.2005.02.4786 1:CAS:528:DC%2BD28Xitl2qtL4%3D 16418498 (Pubitemid 46638855)
27. LH Sehn B Berry M Chhanabhai, et al. 2007 The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP Blood 109 1857 1861 10.1182/blood-2006-08-038257 1:CAS:528:DC%2BD2sXjtFeqt7g%3D 17105812 (Pubitemid 46348180)
28. N Mounier J Briere C Gisselbrecht, et al. 2003 Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL) Blood 101 4279 4284 10.1182/blood-2002-11-3442 1:CAS:528:DC%2BD3sXktFKht7k%3D 12576316 (Pubitemid 36857789)
29. H Nyman M Adde ML Karjalainen-Lindsberg, et al. 2007 Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy Blood 109 4930 4935 10.1182/blood-2006-09-047068 1:CAS:528:DC%2BD2sXmt1Ogu7Y%3D 17299093 (Pubitemid 46827791)
30. R Seki T Ohshima T Fujisaki, et al. 2009 Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era Cancer Sci 100 1842 1847 10.1111/j.1349-7006.2009.01268.x 1:CAS:528:DC%2BD1MXht12qs7jN 19656156
31. TP Miller S Dahlberg JR Cassady, et al. 1998 Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma N Engl J Med 339 21 26 10.1056/NEJM199807023390104 1:STN:280:DyaK1c3pvFersA%3D%3D 9647875 (Pubitemid 28304493)
32. F Reyes E Lepage G Ganem, et al. 2005 ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma N Engl J Med 352 1197 1205 10.1056/NEJMoa042040 1:CAS:528:DC%2BD2MXisFSht7k%3D 15788496 (Pubitemid 40397261)
33. D Persky J Unger C Spier, et al. 2008 Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited stage aggressive B-cell lymphoma: Southwest Oncology Group Study 0014 J Clin Oncol 26 2258 2262 10.1200/JCO.2007.13.6929 1:CAS:528:DC%2BD1cXntVOltrw%3D 18413640
34. N Milpied E Deconinck F Gaillard, et al. 2004 Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support N Engl J Med 350 1287 1295 10.1056/NEJMoa031770 1:CAS:528:DC%2BD2cXisFyiur4%3D 15044639 (Pubitemid 38375363)